Idexx Laboratories (IDXX) Accumulated Expenses (2009 - 2026)

Idexx Laboratories' Accumulated Expenses history runs 18 years deep, the most recent figure standing at $453.6 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 7.57% year-over-year to $453.6 million; the TTM figure through Mar 2026 stood at $453.6 million (down 7.57% YoY), while the FY2025 annual figure was $530.1 million, up 5.58% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $453.6 million, down from $530.1 million in the prior quarter.
• The five-year high for Accumulated Expenses was $541.1 million in Q2 2024, with the low at $387.5 million in Q2 2022.
• The 5-year median for Accumulated Expenses is $453.6 million (2026), against an average of $455.9 million.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses surged 35.48% in 2024, then dropped 22.94% in 2025.
• Idexx Laboratories' Accumulated Expenses stood at $433.7 million in 2022, then rose by 10.39% to $478.7 million in 2023, then gained by 4.89% to $502.1 million in 2024, then rose by 5.58% to $530.1 million in 2025, then decreased by 14.45% to $453.6 million in 2026.
• Business Quant data shows IDXX's Accumulated Expenses at $453.6 million in Q1 2026, $530.1 million in Q4 2025, and $488.9 million in Q3 2025.